|MDACC Study No:||2011-0520 (clinicaltrials.gov NCT No: NCT01444716)|
|Title:||Phase II Study of Ofatumumab as Front-line Treatment in Elderly, Unfit Patients with Chronic Lymphocytic Leukemia (CLL)|
|Principal Investigator:||Alessandra Ferrajoli|
|Study Description:||The goal of this clinical research study is to learn if ofatumumab can help to |
control CLL. The safety of this drug will also be studied.
Ofatumumab is designed to bind to the surface of the leukemia cells . This may
cause the leukemia cells to die.